Binds Lymphokine, Cytokine, Or Other Secreted Growth Regulatory Factor, Differentiation Factor, Or Intercellular Mediator Specific For A Hematopoietic Cell (e.g., Interleukin, Interferon, Erythropoietin, Etc.) Patents (Class 530/388.23)
-
Patent number: 7226593Abstract: Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-?(TNF?) and are useful in vivo diagnosis and therapy of a number of TNF?-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided.Type: GrantFiled: January 10, 2002Date of Patent: June 5, 2007Assignees: Centocor, Inc., New York UniversityInventors: Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight, Scott Siegel
-
Patent number: 7223394Abstract: Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor a (hTNF?) are disclosed. These antibodies have high affinity for hTNF? (e.g., Kd=10?8 M or less), a slow off rate for hTNF? dissociation (e.g., Koff=10?3 sec?1 or less) and neutralize hTNF? activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNF? and for inhibiting hTNF? activity, e.g., in a human subject suffering from a disorder in which hTNF? activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.Type: GrantFiled: March 7, 2001Date of Patent: May 29, 2007Assignee: Abbott Biotechnology LtdInventors: Jochen G. Salfeld, Deborah J. Allen, Hendricus R. J. M. Hoogenboom, Zehra Kaymakcalan, Boris Labkovsky, John A. Mankovich, Brian T. McGuinness, Andrew J. Roberts, Paul Sakorafas, David Schoenhaut, Tristan J. Vaughan, Michael White, Alison J. Wilton
-
Patent number: 7223396Abstract: Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-? (TNF?) and are useful in vivo diagnosis and therapy of a number of TNF?-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided.Type: GrantFiled: December 12, 2002Date of Patent: May 29, 2007Assignees: Centocor, Inc., New York UniversityInventors: Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight, Scott Siegel
-
Patent number: 7220840Abstract: The present invention relates to antibodies and related molecules that immunospecifically bind to B Lymphocyte Stimulator. The present invention also relates to methods and compositions for detecting or diagnosing a disease or disorder associated with aberrant B Lymphocyte Stimulator expression or inappropriate function of B Lymphocyte Stimulator comprising antibodies or fragments or variants thereof or related molecules that immunospecifically bind to B Lymphocyte Stimulator. The present invention further relates to methods and compositions for preventing, treating or ameliorating a disease or disorder associated with aberrant B Lymphocyte Stimulator expression or inappropriate B Lymphocyte Stimulator function comprising administering to an animal an effective amount of one or more antibodies or fragments or variants thereof or related molecules that immunospecifically bind to B Lymphocyte Stimulator.Type: GrantFiled: November 14, 2002Date of Patent: May 22, 2007Assignee: Human Genome Sciences, Inc.Inventors: Steven M. Ruben, Gil H. Choi, Tristan Vaughan, David Hilbert
-
Patent number: 7217529Abstract: The present invention relates to a novel CK?-6 protein which is a member of the alpha chemokine family. In particular, isolated nucleic acid molecules are provided encoding the human CK?-6 protein. CK?-6 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of CK?-6 activity. Also provided are diagnostic methods for detecting CNS and immune system-related disorders and therapeutic methods for treating CNS and immune system-related disorders.Type: GrantFiled: March 16, 2005Date of Patent: May 15, 2007Assignee: Human Genome Sciences, Inc.Inventors: Ying-Fei Wei, Steven M. Ruben, Craig A. Rosen
-
Patent number: 7214375Abstract: The present invention provides a method for treating or arresting the progress of pathologies characterized by an accumulation of extracellular matrix components by providing an agent to suppress the activity of transforming growth factor ? (TGF-?) a peptide growth factor which is anabolic and leads to fibrosis and angiogenesis. In one embodiment, such agent is anti-TGF-? antibody. Pathologies which can be so treated include, but are not limited to, glomerulonephritis, adult respiratory distress syndrome and cirrhosis of the liver. The invention further provides a method for the diagnosis of pathologies, or incipient pathologies, which are characterized by the accumulation of extracellular matrix components in tissues by determining the levels of TGF-? in the tissues, a high level being indicative of such pathologies.Type: GrantFiled: December 2, 1994Date of Patent: May 8, 2007Assignee: La Jolla Cancer Research FoundationInventors: Wayne A. Border, Erkki I. Ruoslahti
-
Patent number: 7214376Abstract: Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-? (TNF?) and are useful in vivo diagnosis and therapy of a number of TNF?-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided.Type: GrantFiled: December 7, 2001Date of Patent: May 8, 2007Assignees: New York University, Centocor, Inc.Inventors: Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight, Scott Siegel
-
Patent number: 7211400Abstract: The present invention relates to compositions and methods of treating and diagnosing disorders characterized the by the presence of antigens associated with inflammatory diseases and/or cancer, and nucleotide sequences, including expressed sequence tags (ESTs), oligonucleotide probes, polypeptides, vectors and host cells expressing such antigens PRO301, PRO362 or PRO245.Type: GrantFiled: January 29, 2004Date of Patent: May 1, 2007Assignee: Genentech, Inc.Inventors: Avi Ashkenazi, Sherman Fong, Audrey Goddard, Austin L. Gurney, Mary A. Napier, Daniel Tumas, William I. Wood
-
Patent number: 7208582Abstract: Disclosed are human VEGF-2 antibodies, antibody fragments, or variants thereof. Also provided are processes for producing such antibodies. The present invention relates to methods and compositions for preventing, treating or ameliorating a disease or disorder comprising administering to an animal, preferably a human, an effective amount of one or more VEGF-2 antibodies or fragments or variants thereof.Type: GrantFiled: April 12, 2002Date of Patent: April 24, 2007Assignee: Human Genome Sciences, Inc.Inventors: Craig A. Rosen, Vivian R. Albert, Steven M. Ruben, Ruth E. Wager
-
Patent number: 7204985Abstract: Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-? (TNF?) and are useful in vivo diagnosis and therapy of a number of TNF?-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided.Type: GrantFiled: February 21, 2003Date of Patent: April 17, 2007Assignees: Centocor, Inc., New York UniversityInventors: Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight, Scott Siegel
-
Patent number: 7202347Abstract: Early developing stage-specific liver proteins and the genes coding for them that have been isolated and sequenced are provided, and these genes and proteins can be utilized to diagnose and/or treat a wide variety of liver disorders and other ailments. Since the early developing liver proteins of the invention arise during embryogenesis when the liver and other organs are in transition from an undifferentiated state to a differentiated one, these proteins are involved in tissue differentiation and thus can be utilized in methods of diagnosing and treating a variety of liver diseases and other disorders including those relating to oncogenesis and tissue repair. Antibodies recognizing early developing liver proteins and peptides are also provided.Type: GrantFiled: October 30, 2003Date of Patent: April 10, 2007Inventor: Lopa Mishra
-
Patent number: 7198790Abstract: Growth differentiation factor-5 (GDF-5) is disclosed along with its polynucleotide sequence and amino acid sequence. Also disclosed are diagnostic and therapeutic methods of using the GDF-5 polypeptide and polynucleotide sequences.Type: GrantFiled: June 12, 2001Date of Patent: April 3, 2007Assignee: The Johns Hopkins University School of MedicineInventors: Se-Jin Lee, Thanh Huynh
-
Patent number: 7196177Abstract: An antibody variable region of a monoclonal antibody specifically binding to human tumor necrosis factor-? contains at least one of a heavy chain variable region and a light chain variable region having specific complementarity determining regions therein. A nucleic acid molecule encoding the same, a recombinant vector containing the nucleic acid molecule, and a cell transformed with the recombinant vector are also provided.Type: GrantFiled: March 16, 2006Date of Patent: March 27, 2007Assignee: Yuhan CorporationInventors: Heui II Kang, In Young Ko, Moo Young Song, Chang Seok Kim, Sang Koo Park, Jae Sun Lee, Tae Hyoung Yoo, Kang In Na
-
Patent number: 7192584Abstract: The invention relates to anti-TNF antibodies, fragments, regions and derivatives thereof which are specific for human tumor necrosis factor-? (TNF?) and are useful in methods of treating psoriasis, as well as polynucleotides coding for murine and chimeric anti-TNF antibodies, and methods of producing anti-TNF antibodies, fragments, regions and derivatives thereof.Type: GrantFiled: August 10, 2001Date of Patent: March 20, 2007Assignees: Centocor, Inc., New York UniversityInventors: Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight, Scott Siegel
-
Patent number: 7189820Abstract: The present invention relates to antibodies and related molecules that immunospecifically bind to Tumor Necrosis Factor Delta (TNF-delta; APRIL). The present invention also relates to methods and compositions for detecting, diagnosing, prognosing, treating, preventing, or ameliorating a disease or disorder associated with aberrant APRIL or APRIL receptor expression or aberrant function of APRIL or APRIL receptor, comprising antibodies or fragments or variants thereof, or related molecules, that immunospecifically bind to APRIL.Type: GrantFiled: May 22, 2002Date of Patent: March 13, 2007Assignee: Human Genome Sciences, Inc.Inventor: Steven M. Ruben
-
Patent number: 7183108Abstract: The invention concerns lactic acid bacteria strains capable of regulating the production of NO and inflammatory cytokines by enterocytes, depending on the inflammatory condition of said enterocytes. The strains can also be incorporated in food supplements such as fermented dairy products used for regulating inflammatory response and non-specific immunity.Type: GrantFiled: November 18, 1999Date of Patent: February 27, 2007Assignee: Compagnie Gervais DanoneInventors: Chantal Cayuela, Nathalie Dugas, Eric Postaire
-
Patent number: 7183390Abstract: The invention provides humanized immunoglobulins that bind to and neutralize ?-interferon. The antibodies are useful for treatment of diseases of the immune system, particularly autoimmune diseases.Type: GrantFiled: November 13, 2001Date of Patent: February 27, 2007Assignee: PDL BioPharma, Inc.Inventors: Maximiliano Vasquez, Nicholas F. Landolfi, Naoya Tsurushita, Cary L. Queen
-
Patent number: 7179466Abstract: Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-? (TNF?) and are useful in vivo diagnosis and therapy of a number of TNF?-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided.Type: GrantFiled: June 28, 2002Date of Patent: February 20, 2007Assignees: New York University, Centocor, Inc.Inventors: Junming Le, Jan Vilcek, Peter Daddona, John Ghraveb, David Knight, Scott Siegel
-
Patent number: 7179893Abstract: Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-? (TNF?) and are useful in vivo diagnosis and therapy of a number of TNF?-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided.Type: GrantFiled: April 7, 2006Date of Patent: February 20, 2007Assignees: New York University, Centocor, Inc.Inventors: Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight, Scott Siegel
-
Patent number: 7169388Abstract: Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-? (TNF?) and are useful in vivo diagnosis and therapy of a number of TNF?-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided.Type: GrantFiled: September 30, 2004Date of Patent: January 30, 2007Assignees: New York University, Centocor, Inc.Inventors: Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight, Scott Siegel
-
Patent number: 7169386Abstract: Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-? (TNF?) and are useful in vivo diagnosis and therapy of a number of TNF?-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided.Type: GrantFiled: January 10, 2002Date of Patent: January 30, 2007Assignees: New York University, Centocor, Inc.Inventors: Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight, Scott Siegel
-
Patent number: 7166284Abstract: Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-? (TNF?) and are useful in vivo diagnosis and therapy of a number of TNF?-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided.Type: GrantFiled: February 21, 2003Date of Patent: January 23, 2007Assignees: New York University, Centocor, Inc.Inventors: Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight, Scott Siegel
-
Patent number: 7166285Abstract: The present invention relates to an anti-IL-12 antibody, including isolated nucleic acids that encode an anti-IL-12 antibody, IL-12, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.Type: GrantFiled: October 28, 2004Date of Patent: January 23, 2007Assignee: Centocor, Inc.Inventors: Jill Giles-Komar, David M. Knight, David Peritt, Bernard Scallon, David Shealy
-
Patent number: 7160543Abstract: Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-? (TNF?) and are useful in vivo diagnosis and therapy of a number of TNF?-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided.Type: GrantFiled: December 8, 2005Date of Patent: January 9, 2007Assignees: New York University, Centocor, Inc.Inventors: Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight, Scott Siegel
-
Patent number: 7160542Abstract: Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-? (TNF?) and are useful in vivo diagnosis and therapy of a number of TNF?-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided.Type: GrantFiled: June 29, 2005Date of Patent: January 9, 2007Assignees: New York University, Centocor, Inc.Inventors: Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight, Scott Siegel
-
Patent number: 7153507Abstract: Isolated human monoclonal antibodies which specifically bind to IL-15 (e.g., human IL-15), and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced in a transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals, and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.Type: GrantFiled: August 23, 2002Date of Patent: December 26, 2006Assignee: Genmab A/SInventors: Jan G. J. van de Winkel, Marcus A. van Dijk, Janine Schuurman, Arnout F. Gerritsen, Ole Baadsgaard
-
Patent number: 7151166Abstract: A mammalian cytokine-like polypeptide, called Mammalian Cytokine-like polypeptide-10, (Zcyto10), polynucleotides encoding the same, antibodies which specifically bind to the polypeptide, and anti-idiotypic antibodies which bind to the antibodies. Zcyto10 is useful for promoting the healing of wounds and for stimulating the proliferation of platelets.Type: GrantFiled: February 27, 2004Date of Patent: December 19, 2006Assignee: ZymoGenetics, Inc.Inventors: Darrell C. Conklin, Betty A. Haldeman
-
Patent number: 7148329Abstract: The present invention relates to the use of a compound that binds to a C-type lectin on the surface of a dendritic cell, in the preparation of a composition for modulating, in particular reducing, the immune response in an animal, in particular a human or another mammal. The composition in particular modulates the interactions between a dendritic cell and a T-cell, more specifically between a C-type lectin on the surface of a dendritic cell and an ICAM receptor on the surface of a T-cell. The compositions can be used for preventing/inhibiting immune responses to specific antigens, for inducing tolerance, for immunotherapy, for immunosuppression, for the treatment of auto-immune diseases, the treatment of allergy, and/or for inhibiting HIV infection. The compound that binds to a C-type lectin is preferably chosen from mannose, fucose, plant lectins, antibiotics, sugars, proteins or antibodies against C-type lectins.Type: GrantFiled: April 19, 2000Date of Patent: December 12, 2006Assignee: Katholieke Universiteit NijmegenInventors: Carl Gustav Figdor, Teunis Bernard Herman Geijtenbeek, Yvette Van Kooyk, Ruurd Torensma
-
Patent number: 7141653Abstract: The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to interleukin 5 (IL-5), which is preferably human IL-5. The invention also relates to human anti-IL-5 antibodies, including chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulin molecules derived from anti-IL-5 antibodies and nucleic acid molecules encoding such molecules. The present invention also relates to methods of making anti-IL-5 antibodies, pharmaceutical compositions comprising these antibodies and methods of using the antibodies and compositions thereof for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-IL-5 antibodies.Type: GrantFiled: March 27, 2003Date of Patent: November 28, 2006Assignees: Schering Corporation, Abgenix, Inc.Inventors: Scott Greenfeder, Jose Corvalan
-
Patent number: 7138501Abstract: The present invention relates to antibodies and related molecules that immunospecifically bind to B Lymphocyte Stimulator. The present invention also relates to methods and compositions for detecting or diagnosing a disease or disorder associated with aberrant B Lymphocyte Stimulator expression or inappropriate function of B Lymphocyte Stimulator comprising antibodies or fragments or variants thereof or related molecules that immunospecifically bind to B Lymphocyte Stimulator. The present invention further relates to methods and compositions for preventing, treating or ameliorating a disease or disorder associated with aberrant B Lymphocyte Stimulator expression or inappropriate B Lymphocyte Stimulator function comprising administering to an animal an effective amount of one or more antibodies or fragments or variants thereof or related molecules that immunospecifically bind to B Lymphocyte Stimulator.Type: GrantFiled: June 15, 2001Date of Patent: November 21, 2006Assignee: Human Genome Sciences, Inc.Inventors: Steven M. Ruben, Gil H. Choi, Tristan Vaughan, David Hilbert
-
Patent number: 7138118Abstract: Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-? (TNF?) and are useful in vivo diagnosis and therapy of a number of TNF?-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided.Type: GrantFiled: December 8, 2005Date of Patent: November 21, 2006Assignees: Centocor, Inc., New York UniversityInventors: Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight, Scott Siegel
-
Patent number: 7138498Abstract: Human chemokine polypeptides and DNA (RNA) encoding such chemokine polypeptides and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such chemokine polypeptides for the treatment of leukemia, tumors, chronic infections, autoimmune disease, fibrotic disorders, wound healing and psoriasis. Antagonists against such chemokine polypeptides and their use as a therapeutic to treat rheumatoid arthritis, autoimmune and chronic inflammatory and infective diseases, allergic reactions, prostaglandin-independent fever and bone marrow failure are also disclosed.Type: GrantFiled: August 25, 2003Date of Patent: November 21, 2006Assignee: Human Genome Sciences, Inc.Inventors: Haodong Li, Mark D. Adams, Solange H. Gentz, Ralph Alderson, Yuling Li, David Parmelee, John R. White, Edward R. Appelbaum
-
Patent number: 7138115Abstract: Method of treating autoimmune conditions are disclosed comprising administering to a mammalian subject IL-12 or an IL-12 antagonist. In certain preferred embodiments the autoimmune condition is one which is promoted by an increase in levels of IFN-? or TNF-?. Suitable conditions for treatment include multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, autoimmune pulmonary inflammation, Guillain-Barre syndrome, autoimmune thyroiditis, insulin dependent diabetes melitis and autoimmune inflammatory eye disease.Type: GrantFiled: September 11, 2003Date of Patent: November 21, 2006Assignee: Genetics Institute, LLCInventors: John P. Leonard, Samuel Goldman, Richard O'Hara, Jr.
-
Patent number: 7135174Abstract: The present invention is related to antibodies directed to the antigen PDGFD and uses of such antibodies. In particular, in accordance with the present invention, there are provided fully human monoclonal antibodies directed to the antigen PDGFD. Nucelotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3, are provided. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also provided.Type: GrantFiled: January 7, 2002Date of Patent: November 14, 2006Assignee: Amgen Fremont, Inc.Inventors: Jose R. F. Corvalan, Xiao-Chi Jia, Xiao Feng, Xiao-dong Yang, Francine Chen, Gadi Gazit, Richard Weber, Binyam Bezabeh
-
Patent number: 7135179Abstract: Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-? (TNF?) and are useful in vivo diagnosis and therapy of a number of TNF?-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided.Type: GrantFiled: July 13, 2005Date of Patent: November 14, 2006Assignees: Centocor, Inc., New York UniversityInventors: Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight, Scott Siegel
-
Patent number: 7135178Abstract: Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-? (TNF?) and are useful for therapy of TNF?-mediated pathologies and conditions, including vascular inflammatory pathologies.Type: GrantFiled: June 20, 2002Date of Patent: November 14, 2006Assignees: Centocor, Inc., New York UniversityInventors: Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight, Scott Siegel
-
Patent number: 7132508Abstract: A novel CC chemokine which is from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding said chemokine. A chemokine receptor is also provided. Methods of using said reagents and diagnostic kits are also provided.Type: GrantFiled: November 13, 2002Date of Patent: November 7, 2006Assignee: Schering CorporationInventors: Daniel J. Dairaghi, Takahiko Hara, Atsushi Miyajima, Thomas J. Schall, Wei Wang, Akihiko Yoshimura
-
Patent number: 7128905Abstract: The present invention is drawn to methods of preventing and treating diseases wherein the involvement of apoptosis has been indicated.Type: GrantFiled: February 28, 2002Date of Patent: October 31, 2006Assignees: Mochida Pharmaceutical Co., Ltd., Osaka Bioscience InstituteInventors: Shigekazu Nagata, Takehiro Yatomi, Takashi Suda
-
Patent number: 7128908Abstract: Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-? (TNF?) and are useful in vivo diagnosis and therapy of a number of TNF?-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided.Type: GrantFiled: July 12, 2005Date of Patent: October 31, 2006Assignees: Centocor, Inc., New York UniversityInventors: Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight, Scott Siegel
-
Patent number: 7128907Abstract: Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-? (TNF?) and are useful in vivo diagnosis and therapy of a number of TNF?-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided.Type: GrantFiled: March 4, 2003Date of Patent: October 31, 2006Assignees: Centocor, Inc., New York UniversityInventors: Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight, Scott Siegel
-
Patent number: 7129054Abstract: The invention relates to an antibody or antibody fragment which specifically binds to a protein of the TGF-? family. The invention also relates to a kit for detecting a protein of the TGF-? family which comprises the antibody or antibody fragment. Finally, the invention relates to method for detecting a protein of the TGF-? family which uses the antibody or antibody fragment.Type: GrantFiled: May 19, 2005Date of Patent: October 31, 2006Assignee: Biopharm Gesellschaft zur Biotechnologischen Entwicklung von Pharmaka mbHInventors: Gertrud Hötten, Helge Neidhardt, Rolf Bechtold, Jens Pohl, Michael Paulista
-
Patent number: 7122639Abstract: Human chemokine Alpha-2-polypeptides and DNA (RNA) encoding such chemotactic cytokines and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are method for utilizing such chemotactic cytokines for the treatment of leukemia, tumors, chronic infections, auto-immune disease, fibrotic disorders, wound healing and psoriasis. Antagonists against such chemotactic cytokines and their use as a therapeutic to treat rheumatoid arthritis, autoimmune and chronic and acute inflammatory and infective diseases, allergic reactions, prostaglandin-independent fever and bone marrow failure are also disclosed. Also disclosed are diagnostic assays for detecting diseases related to mutations in the nucleic acid sequences and altered concentrations of the polypeptides. Also disclosed are diagnostic assays for detecting mutations in the polynucleotides encoding the chemotactic cytokines and for detecting altered levels of the polypeptides in a host.Type: GrantFiled: October 10, 2002Date of Patent: October 17, 2006Assignee: Human Genome Sciences, Inc.Inventors: Jian Ni, Reiner L. Gentz, Jeffrey Y. Su, Haodong Li
-
Patent number: 7122183Abstract: The invention provides methods of treating autoimmune and chronic inflammatory conditions by administering agents that hinder the CD30/CD30L interaction, combination treatments, and methods of treating conditions resistant to treatment with TNF? inhibitors by administering agents that inhibit signal transduction by CD30 or IL-1. Included also are treatments involving concurrently administering agents that block the CD30/CD30L interaction and agents that antagonize the IL-4/IL-4R interaction. Additionally provided is an animal model for screening candidate agents for their efficacy in treating conditions that are resistant to treatment with TNF? inhibitors.Type: GrantFiled: August 26, 2003Date of Patent: October 17, 2006Assignee: Immunex CorporationInventors: Kendall M. Mohler, Dauphine S. Barone, Jacques J. Peschon, Mary K. Kennedy, John D. Pluenneke
-
Patent number: 7119175Abstract: A mammalian cytokine-like polypeptide, called Zcyto10, polynucleotides encoding the same, antibodies which specifically bind to the polypeptide, and anti-idiotypic antibodies which bind to the antibodies. Zcyto10 is useful for promoting the healing of wounds and for stimulating the proliferation of platelets.Type: GrantFiled: December 29, 2003Date of Patent: October 10, 2006Assignee: ZymoGenetics, Inc.Inventors: Darrell C. Conklin, Betty A. Haldeman, Angelika Grossmann
-
Patent number: 7115263Abstract: The present invention comprises and utilizes methods and compositions for treating hyperimmune reactions in the eye. Compositions comprising antibodies to gamma interferon alone and in combination with other drugs are described. Also disclosed in the invention are methods of applying a composition comprising interferon gamma antibodies topically to the eye to treat hyperimmune reactions, such as transplant rejection, uveitis, autoimmune diseases of the eye, and ocular disorders incidental to or connected with autoimmune diseases.Type: GrantFiled: February 28, 2005Date of Patent: October 3, 2006Assignee: Advanced Biotherapy, Inc.Inventors: Boris Skurkovich, Simon Skurkovich
-
Patent number: 7115379Abstract: Nucleic acids encoding a new family of chemokines, the CX3C family, from a mammal, reagents related thereto, including specific antibodies, and purified proteins are described. Methods of using said reagents and related diagnostic kits are also provided.Type: GrantFiled: March 25, 2003Date of Patent: October 3, 2006Assignee: Schering CorporationInventors: Gerard T. Hardiman, Devora L. Rossi, Kevin B. Bacon, Fernando J. Bazan, Thomas B. Schall, Albert Zlotnik
-
Patent number: 7109308Abstract: Disclosed is a human VEGF2 polypeptide and DNA(RNA) encoding such VEGF2 polypeptides. Also provided is a procedure for producing such polypeptide by recombinant techniques and antibodies and antagonist against such polypeptide. Also disclosed is a method of using such polypeptide for stimulating wound healing and for vascular tissue repair. Also provided are methods of using the antagonists to inhibit tumor growth, inflammation and to treat diabetic retinopathy, rheumatoid arthritis and psoriasis. Diagnostic methods for detecting mutations in the VEGF2 coding sequence and alterations in the concentration of VEGF2 protein in a sample derived from a host are also disclosed.Type: GrantFiled: December 21, 2001Date of Patent: September 19, 2006Assignee: Human Genome Sciences, Inc.Inventors: Craig A. Rosen, Jing-Shan Hu, Liang Cao
-
Patent number: 7105644Abstract: The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins. Disclosed embodiments of the invention also include antibodies that bind to secreted protein HHTLF25 and methods for making and using such antibodies.Type: GrantFiled: October 25, 2001Date of Patent: September 12, 2006Assignee: Human Genome Sciences, Inc.Inventors: Craig A. Rosen, Steven M. Ruben, David W. LaFleur
-
Patent number: 7101978Abstract: The present invention relates to TNF-? binding molecules and nucleic acid sequences encoding TNF-? binding molecules. In particular, the present invention relates to TNF-? binding molecules with a high binding affinity, a high association rate, a low dissociation rate with regard to human TNF-? and that are capable of neutralizing TNF-? at low concentrations. Preferably, the TNF-? binding molecules of the present invention comprise light and/or heavy chain variable regions with fully human frameworks (e.g. human germline frameworks).Type: GrantFiled: January 8, 2003Date of Patent: September 5, 2006Assignee: Applied Molecular EvolutionInventors: Jeffry D. Watkins, Alain P. Vasserot, David Marquis, William D. Huse
-
Patent number: RE39548Abstract: An effective anti-IL-5 recombinant antibody molecule comprising heavy and/or light chain antigen-binding residues from a donor antibody.Type: GrantFiled: December 7, 2001Date of Patent: April 3, 2007Assignee: Celltech R&D LimitedInventors: Mark William Bodmer, Diljeet Singh Athwal, John Spencer Emtage